A New F-18 Labeled PET Agent For Imaging Alzheimer's Plaques
- UT Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390 (United States)
- CAMH PET Centre and Department of Psychiatry, University of Toronto, Toronto ONT, M5T-1R8 (Canada)
Amyloid plaques and neurofibrillary tangles are hallmarks of Alzheimer's disease (AD). Advances in development of imaging agents have focused on targeting amyloid plaques. Notable success has been the development of C-11 labeled PIB (Pittsburgh Compound) and a number of studies have demonstrated the utility of this agent. However, the short half life of C-11 (t1/2: 20 min), is a limitation, thus has prompted the development of F-18 labeled agents. Most of these agents are derivatives of amyloid binding dyes; Congo red and Thioflavin. Some of these agents are in clinical trials with encouraging results. We have been exploring new class of agents based on 8-hydroxy quinoline, a weak metal chelator, targeting elevated levels of metals in plaques. Iodine-123 labeled clioquinol showed affinity for amyloid plaques however, it had limited brain uptake and was not successful in imaging in intact animals and humans. We have been successful in synthesizing F-18 labeled 8-hydroxy quinoline. Small animal PET/CT imaging studies with this agent showed high (7-10% ID/g), rapid brain uptake and fast washout of the agent from normal mice brains and delayed washout from transgenic Alzheimer's mice. These promising results encouraged us in further evaluation of this class of compounds for imaging AD plaques.
- OSTI ID:
- 21519893
- Journal Information:
- AIP Conference Proceedings, Vol. 1336, Issue 1; Conference: CAARI 2010: 21. International Conference on the Application of Accelerators in Research and Industry, Fort Worth, TX (United States), 8-13 Aug 2010; Other Information: DOI: 10.1063/1.3586125; (c) 2011 American Institute of Physics; ISSN 0094-243X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease
Amelioration of Alzheimer’s disease pathology and cognitive deficits by immunomodulatory agents in animal models of Alzheimer’s disease
Related Subjects
AZO DYES
BRAIN
CARBON 11
CLINICAL TRIALS
FLUORINE 18
IODINE 123
MICE
NERVOUS SYSTEM DISEASES
NMR IMAGING
PROTEINS
SULFONIC ACIDS
TOMOGRAPHY
UPTAKE
ANIMALS
AZO COMPOUNDS
BETA DECAY RADIOISOTOPES
BETA-PLUS DECAY RADIOISOTOPES
BODY
CARBON ISOTOPES
CENTRAL NERVOUS SYSTEM
DIAGNOSTIC TECHNIQUES
DISEASES
DYES
ELECTRON CAPTURE RADIOISOTOPES
EVEN-ODD NUCLEI
FLUORINE ISOTOPES
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LIGHT NUCLEI
MAMMALS
MINUTES LIVING RADIOISOTOPES
NANOSECONDS LIVING RADIOISOTOPES
NERVOUS SYSTEM
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
ORGANIC ACIDS
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANIC SULFUR COMPOUNDS
ORGANS
RADIOISOTOPES
RODENTS
TESTING
VERTEBRATES